Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Constantine S. Tam on BCL2 Inhibitors Compared to Ibrutinib, Idelalisib

Constantine S. Tam, MD
Published: Wednesday, Sep 28, 2016


Constantine S. Tam, MD, Consultant Hematologist, Division of Hematology and Oncology, Peter MacCallum Cancer Center, Melbourne, Australia discusses BCL2 inhibitors in chronic lymphocytic leukemia (CLL).
 
BCL2 inhibitors are very active in CLL. One challenge is selecting between BCL2 inhibitors and agents like Ibrutinib and idelalisib, said Tam.
 
Ibrutinib and idelalisib are very effective in most patients, but rarely achieve complete remission. The BCL2 inhibitor venetoclax, especially in combination with rituximab, regularly allow patients to achieve complete remission and minimal residual disease, said Tam.
 
A major factor in choosing one class over the over is the intention for treatment. If an oncologist wants a low-side effect therapy that will be given over a long period of time, ibrutinib and idelalisib are the ideal. If they are looking to eventually stop therapy all together a BCL2 inhibitors is the best option.
 
There are also combination studies combining ibrutinib with venetoclax, which may have potential.
 

Constantine S. Tam, MD, Consultant Hematologist, Division of Hematology and Oncology, Peter MacCallum Cancer Center, Melbourne, Australia discusses BCL2 inhibitors in chronic lymphocytic leukemia (CLL).
 
BCL2 inhibitors are very active in CLL. One challenge is selecting between BCL2 inhibitors and agents like Ibrutinib and idelalisib, said Tam.
 
Ibrutinib and idelalisib are very effective in most patients, but rarely achieve complete remission. The BCL2 inhibitor venetoclax, especially in combination with rituximab, regularly allow patients to achieve complete remission and minimal residual disease, said Tam.
 
A major factor in choosing one class over the over is the intention for treatment. If an oncologist wants a low-side effect therapy that will be given over a long period of time, ibrutinib and idelalisib are the ideal. If they are looking to eventually stop therapy all together a BCL2 inhibitors is the best option.
 
There are also combination studies combining ibrutinib with venetoclax, which may have potential.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x